Bordeaux, France-based Implanet entered into an exclusive distribution agreement with Device Technologies for the Australia and New Zealand markets.
Here are four key points:
1. With this partnership, Implanet markets in 17 countries.
2. Implanet will now have access to Australia's $120 million vertebral fusion market, to offer its Jazz products.
3. Implanet also integrated its Jazz Claw into the Australian Register of Therapeutic Goods.
4. Jazz is designed to treat spinal pathologies with vertebral fusion surgery.